Horizon Pharma PLC (NASDAQ:HZNP) has grabbed the attention from analysts, when it saw a value decrease of -1.98 percent or -0.20 points in the last trading session. A total of 13.45M shares exchanged hands during the intra-day trade compared with its average trading volume of 3.76M shares, while its relative volume stands at 4.10. Horizon Pharma PLC (NASDAQ:HZNP) has a market cap of $1.65B and the number of outstanding shares have been calculated 162.71M.
When taking a look at recommendations from analysts, investors can use the average brokerage recommendation score to determine the consensus take on a stock. The ABR is the calculated average of the actual recommendations (strong buy, hold, sell etc) made by the brokerage firms for a given stock. The ABR rank is displayed in the range of 1 to 5 where 1 represents a Strong Buy and 5 a Strong Sell. The ABR is solely based on brokerage recommendations. It’s important to note that analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Shares of Horizon Pharma PLC (NASDAQ:HZNP) currently have an ABR of 1.33, number of Recs in ABR is 6 while industry rank of the company by ABR is 153 of 265.
Out of the brokerage recommendations 5 rate Horizon Pharma PLC (NASDAQ:HZNP) stock a Strong Buy, 0 rate the stock a Buy, 1 rate Hold, 0 rate Sell and 0 recommend a Strong Sell.
Taking a glance at where the stock might be directed in the future, on a consensus basis, the sell-side has a 52 week price target of $16.80 on the stock, this valuation is based on 10 number of opinions with standard deviation of 8.30. Most recently Horizon Pharma PLC (NASDAQ:HZNP)’s price target was revised on 04/23/17. The most optimistic analyst sees the stock reaching $22 while the most conventional has $10 target price if we look at the price target with an optimistic approach it has upside potential of 117% from its recent closing price of $9.92.
Historically, if we have a peek at price target revisions, Horizon Pharma PLC (NASDAQ:HZNP)’s price target was revised by the analysts two weeks back on 04/10/17 to set its target price at $29.17 where its twelve month high target price was set at $42 and low at $20 while demonstrating the standard deviation of 8.30.
In order to check on the sell-side rational, we can also take a peek at some technical indicators. Horizon Pharma PLC (NASDAQ:HZNP)’s price sits -34.18% off from its 50-day moving average of $14.87 and -43.51% away from the stock’s 200-day moving average which is $16.64. The stock hit its 52-week high on 08/15/16 and 52-week low on 05/09/17. The average true range, a measure of volatility is at 0.77, however its weekly and monthly volatility is 5.09%, 3.26% respectively. The company’s Relative Strength Index which shows price strength currently stands at 45.
Horizon Pharma PLC (NASDAQ:HZNP) as of recent trade, has shown weekly downbeat performance of -37.02 percent which was maintained at -33.78 percent in 1-month period. The year-to-date (YTD) performance reflected -38.69 percent negative outlook. During the past three months the stock slid -40.35 percent, bringing six-month performance to -34.09 percent.
While taking a glance at financials, we can look at a number of key indicators. Horizon Pharma PLC (NASDAQ:HZNP) has a Return on Assets of -4.70%, which is key indicator of how profitable a company is relative to its total assets. The company currently has a Return on Equity of -12.70% and a Return on Investment of -2.80%. ROI is a performance measure used to evaluate the efficiency of an investment or to compare the efficiency of a number of different investments.
The stock has a current PEG ratio of 0.88 whereas its trailing twelve month P/E ratio is -9.54 along with forward price to earnings ratio of 3.80. Horizon Pharma PLC (NASDAQ:HZNP)’s price to free cash flow for trailing twelve months is 4.52. Its quick ratio for most recent quarter is 1.40 along with current ratio for most recent quarter of 1.70. Total debt to equity ratio of the company for most recent quarter is 1.43 whereas long term debt to equity ratio for most recent quarter is 1.42.